Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832029 | PMC |
| http://dx.doi.org/10.1080/10428194.2016.1248964 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).
Transplant Cell Ther
November 2024
Division of Hematology and Oncology, Department of Medicine, New York-Presbyterian Hospital/Weill Cornell Medicine, New York, New York. Electronic address:
Despite the established potentially curative role of allogeneic hematopoietic cell transplantation (allo-HCT) in managing myelofibrosis (MF), the choice of alternative donors for patients lacking matched donors remains a challenge, and the optimal graft source in this disease entity continues to be an ongoing debate. We aimed to evaluate the impact of donor type: umbilical cord blood transplant supported with CD34+ selected haploidentical donor (haplo-cord) versus adult matched related donor (MRD) and matched unrelated donor (MUD) in 40 adult patients with primary or secondary MF, including those progressing to accelerated phase (AP) or blast phase (BP), who underwent their first allo-HCT. The primary objective of this study was to analyze the impact of stem cell source on primary endpoints of overall survival (OS), graft-versus-host disease, and non-relapse mortality (NRM).
View Article and Find Full Text PDFOutcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis.
Transplant Cell Ther
August 2024
The University of Colorado School of Medicine, Division of Hematology, Aurora, Colorado. Electronic address:
Despite the concurrent use of haploidentical cord (HCT) and dual cord (DCT) stem cell transplant approaches for over a decade, there have been few comparisons of their outcomes. Our objective in this study is to assess for differences in the outcomes and adverse effects associated with HCTs versus DCTs. Here we report a retrospective analysis of HCTs and DCTs at our institution.
View Article and Find Full Text PDFThe combination of cord blood transplant with progenitor cells from partially HLA-matched adult donors has been used over the past two decades. In Europe and the US the adult donor graft is CD34 selected and provides early hematopoiesis, but durable engraftment derives from the cord blood graft . Neutrophil recovery is prompt and rates of acute and chronic GVHD are low.
View Article and Find Full Text PDFHaploidentical hematopoietic cell transplantation with or without an unrelated cord blood unit for adult acute myeloid leukemia: a multicenter, randomized, open-label, phase 3 trial.
Signal Transduct Target Ther
May 2024
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Article Synopsis
- Scientists did a study to see if a special transplant method called haplo-cord HCT is better for people with a type of blood cancer called acute myeloid leukemia (AML).
- They found that patients who got haplo-cord HCT had a better chance of surviving after 3 years compared to those who had the regular haplo-HCT.
- Also, haplo-cord HCT helped patients recover faster and had good results without causing too many side effects.
[Haploidentical donor peripheral blood stem cell transplantation using third-party cord blood compared with matched unrelated donor transplantation for patients with hematologic malignancies].
Zhonghua Xue Ye Xue Za Zhi
February 2024
Department of Hematology, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Diseases (Xiangya Hospital) ; Hunan Clinical Medical Research Center of Hematologic Neoplasms, Changsha 410008, China.
To assess the efficacy of cord blood-assisted haploid peripheral blood stem cell transplantation (haplo-cord-PBSCT) versus unrelated donor peripheral blood stem cell transplantation (UD-PBSCT) in the treatment of malignant hematological diseases. A retrospective analysis was performed on one hundred and four patients with malignant hematological diseases who underwent haplo-cord-PBSCT and fifty-two patients who underwent UD-PBSCT at Xiangya Hospital of Central South University between January 2016 and December 2021. ①The median implantation time for neutrophils in the haplo-cord-PBSCT and UD-PBSCT groups was 13 (9-22) days and 13 (10-24) days, respectively (=0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!